AstraZeneca Pharma India reports net loss of Rs 8.14 crore in Q1

Astrazeneca Pharma India Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 506820 | NSE: ASTRAZEN

11 Aug 2012 Evaluate

AstraZeneca Pharma India has reported results for first quarter ended June 30, 2012.

On standalone basis, the company has reported a net loss of Rs 8.14 crore for the quarter ended June 30, 2012 against net profit of Rs 16.74 crore for the corresponding period last fiscal. Total income decreased by 28.68% at Rs 99.12 crore during the quarter under review from Rs 138.98 crore in the year-ago period.

AstraZeneca operates through two entities, AstraZeneca Pharma India and AstraZeneca India in the country.

Peers

Company Name	CMP
Sun Pharma. Inds.	1835.50
Dr. Reddys Labs.	1171.10
Cipla	1371.45
Lupin	2144.70
Zydus Lifesciences	1153.00
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.